The objectives of the meeting were:

1. To define the public health needs, and their evidence base, for FDCs for priority communicable diseases;

2. To determine the issues to be addressed from clinical, regulatory, intellectual property and production perspectives to overcome barriers to the availability of required/preferred FDCs.